Drugs / CAR-T
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06963866 | May 2025 → Apr 2028 expected | plasma cell myeloma | Xuzhou Medical University | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CAR-T | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06963866 ↗ |
| Modality | Cell therapy | “The T cells are genetically modified to express a chimeric antigen receptor targeting BCMA” NCT06963866 ↗ |